Macrophage Migration Inhibitory Factor –173GC Variant Might Increase the Risk of Behçet’s Disease

Ayse Feyda Nursal\textsuperscript{a} Serbulent Yigit\textsuperscript{b} Ercan Tural\textsuperscript{c} Goknur Kalkan\textsuperscript{d} Mehmet Kemal Tumer\textsuperscript{e} Akin Tekcan\textsuperscript{f}

\textsuperscript{a}Department of Medical Genetics, Faculty of Medicine, Hitit University, Corum, Turkey; \textsuperscript{b}Department of Medical Biology, Faculty of Medicine, Gaziosmanpasa University, Tokat, Turkey; \textsuperscript{c}Havza Vocational School, Department of Physiotherapy Programme, Ondokuz Mayis University, Samsun, Turkey; \textsuperscript{d}Department of Dermatology, Faculty of Medicine, Yildirim Beyazit University, Ankara, Turkey; \textsuperscript{e}Department of Maxillofacial Surgery, Faculty of Dentistry, Gaziosmanpasa University, Tokat, Turkey; \textsuperscript{f}Department of Medical Biology, Faculty of Medicine, Ahi Evran University, Kirsehir, Turkey

\textbf{Significance of the Study}

- In this study, individuals with the MIF gene –173GC variant CC genotype were more likely to develop Behçet’s disease in a Turkish group. Therefore, the MIF –173GC variant could be a potential biological marker for the occurrence of Behçet’s disease.

\textbf{Keywords}
Behçet’s disease · Macrophage migration inhibitory factor · Variant

\textbf{Abstract}

\textbf{Objective:} The aim of the present study was to investigate any possible association between the macrophage migration inhibitory factor (MIF) –173GC variant and Behçet’s disease (BD) in a group of Turkish patients. 

\textbf{Subjects and Methods:} A total of 111 patients with BD and 100 healthy controls were enrolled in this study. Genomic DNA was extracted from peripheral lymphocytes. The MIF –173GC variant was genotyped using polymerase chain reaction restriction fragment length polymorphism. The allele and genotype frequencies of patients and controls were compared using the $\chi^2$ test. 

\textbf{Results:} A statistically significant difference in the distribution of the genotype was observed between BD patients and healthy controls. The homo-genotype CC was more prevalent in the patient group compared to the control group ($p = 0.008$, OR: 0.24, 95% CI: 0.05–0.78). A significant association was observed when the patients were compared with the controls according to GG + GC versus CC genotypes ($p = 0.003$, OR: 1.21, 95% CI: 0.06–0.063). Allele frequencies of the MIF –173GC variant did not show any statistically significant difference between patients and controls. 

\textbf{Conclusion:} In this study, we conclude that the CC genotype of the MIF –173GC variant may be a risk factor in the pathogenesis of BD in the Turkish population. However, further studies with larger samples are needed to address the exact role of this variant in BD.

© 2018 The Author(s)
Published by S. Karger AG, Basel
Introduction

Behçet’s disease (BD) is a chronic relapsing systemic inflammatory illness; it manifests as oral and genital ulcers, skin lesions, and uveitis [1]. Arthritis, vasculitis, central nervous system disease and gastrointestinal ulceration are among the other manifestations [1]. BD is more common along the Mediterranean coast and in Eastern Asia [1]. The etiology remains still unknown; however, it has been suggested that BD could be a result of various environmental triggering factors, ranging from infectious agents to pollutants. This disease is also subject to background genetic susceptibility [1]. Four factors imply a genetic impact on BD susceptibility: geographical distribution, familial aggregation, association with HLA-B51 class I antigen, and polymorphisms in genes that modulate immune responses [2]. Some studies in different ethnic groups have shown that there is a correlation between HLA-B51 and BD, and this correlation with HLA-B51 is believed to be the strongest genetic susceptibility factor for BD, and it is assumed to be involved in neutrophil activation [1]. Cytokines play crucial roles in the pathogenesis of BD, due to their impact and regulatory functions in immune and inflammatory reactions [3]. Overexpression of proinflammatory cytokines, mainly Th1 and Th17 from several cellular sources, seems to account for the increased inflammatory response in BD and may be linked with genetic susceptibility [2].

Macrophage migration inhibitory factor (MIF) is a crucial proinflammatory cytokine with a strong modulatory impact on immune and inflammatory responses [4]. MIF is produced in response to various stimuli such as lipopolysaccharide, proinflammatory cytokines including tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), and hypoxia [4]. The MIF gene (Genbank GeneID:307284) is located in chromosome 22q11.2 in humans [5]. One of them is a single-nucleotide polymorphism at position −173 (rs755622) [6]. It has been suggested that the functional impact of MIF−173GC accounts for the formation of a binding site for the transcription factor AP4 [7]. This variant is related to high plasma concentrations of MIF, enhanced risk and severity of inflammatory disease, and decreased response to glucocorticoid medication [8].

The −173 C allele has been associated with an increased production of MIF protein [8]. So far, the association between the MIF−173GC functional variant and BD has not been fully studied. In this study, we investigated the relationship between the MIF−173GC variant and BD for the first time in a group of Turkish patients.

Subjects and Methods

Study Population

One hundred eleven patients with BD were studied in the Dermatology Department of Gaziosmanpasa University Research Hospital, Tokat, Turkey. Forty-three of the patients were male and 68 were female. Medical assessments were performed by dermatologists using the International Study Group criteria for BD [9]. Detailed clinical characteristics including disease duration, treatment duration, aphthous stomatitis, genital involvement, skin lesions (papulopustules, erythema nodosum), ocular involvement, deep vein thrombosis, skin involvement, dosage of colchicine, and response of colchicine were reported by dermatologists.

The control group included 100 healthy controls, 41 males and 59 females. Controls were selected from healthy individuals who had no history of any chronic and autoimmune disease. The mean age of the patients and controls was 36.0 ± 9.4 and 38.5 ± 9.2 years, respectively. All participants were informed of the study protocol, and written informed consent was obtained from them. The Institutional Ethics Committee approved this study which was conducted in accordance with the Helsinki Declaration.

Genotyping

Blood samples were drawn from all subjects. Deoxyribonucleic acid (DNA) was extracted from whole-blood samples using a DNA extraction kit, according to the manufacturer’s instructions (Sigma-Aldrich, Taufkirchen, Germany). The MIF −173GC variant was genotyped in all the subjects by the polymerase chain reaction (PCR) restriction fragment length polymorphism analysis, as described previously [10, 11]. A set of primers, 5′-ACT-AAG-AAG-GAC-AGG-C-3′ (forward) and 5′-GGG-GCA-CGT-TTG-TGT-ATA-C-3′ (reverse), was used to amplify the MIF −173GC site. Genomic DNA was amplified in a 25-μL final reaction. PCR cycles were 95 °C (5 min) for 1 cycle, followed by 95 °C (45 s), 60 °C (45 s), and 72 °C (45 s) for 30 cycles. A final cycle of 72 °C for 7 min completed the reaction. The amplified PCR product was digested in a 30-μL final reaction volume using 2 μL of reaction buffer and 1 μL of AluI restriction enzyme at 37 °C for 12 h. Controls of known genotypes were included for every set of digestions carried out. The digested products were resolved on 2% agarose gel stained with ethidium bromide and visualized using ultraviolet transillumination. Two fragments (268 and 97 bp) were observed when the C allele was present at position −173, while 3 fragments (206, 97, and 62 p) were observed when the G allele was present.

Statistical Analysis

All statistical analyses were performed with the Statistical Package for the Social Science for Windows (version 18.0; SPSS Inc., Chicago, IL, USA) Statistical Program Version 16.0 and the Open-Epi info 2.2 software package program. Continuous data were given as means ± SD and minimum/maximum. The χ² test was used to measure significance of differences in the allele frequency and genotype distribution between the two study groups. Odds ratio (OR) and 95% confidence intervals (CI) were calculated. A p value <0.05 was considered statistically significant.
Table 1. Clinical and demographic features of controls and patients with BD

| Characteristic                        | Control group          | Patient group          |
|--------------------------------------|------------------------|------------------------|
| Gender (male/female), n (%)          | 41/59 (40.60/59.40)    | 43/68 (38.7/61.3)      |
| Age (mean ± SD), years               | 38.48±9.24             | 36.00±9.39             |
| Disease duration (mean ± SD), years  | 7.45±6.82              | 5.93±6.70              |
| Treatment duration (mean ± SD), years|                       |                        |
| Aphthous stomatitis                  |                        |                        |
| No/yes, %                            | –                      | 0/100                  |
| Genital involvement                  |                        |                        |
| No/yes, %                            | –                      | 12/67/87.4             |
| Papulopustule                        |                        |                        |
| No/yes, %                            | –                      | 27/73                  |
| Erythema nodosum                     |                        |                        |
| No/yes, %                            | –                      | 45.9/54.1              |
| Ocular involvement                   |                        |                        |
| No/yes, %                            | –                      | 8.1/91.9               |
| Deep vein thrombosis                 |                        |                        |
| No/yes, %                            | –                      | 25.2/74.8              |
| Skin involvement                     |                        |                        |
| No/yes, %                            | –                      | 5.4/94.6               |
| Dosage of colchicine, %              |                        |                        |
| 500 mg/kg                            | –                      | 4.8                    |
| 1,000 mg/kg                          | –                      | 21                     |
| 1,000–1,500 mg/kg                    | –                      | 17.1                   |
| 1,500 mg/kg                          | –                      | 57.1                   |
| Response to colchicine               |                        |                        |
| No/yes, %                            | –                      | 33/67                  |

SD, standard deviation.

Table 2. Genotype and allele frequencies of the MIF –173GC variant in patients and controls

| MIF                   | Patients (n = 111), n (%) | Controls (n = 100), n (%) | p     | OR (95% CI) |
|-----------------------|---------------------------|---------------------------|-------|-------------|
| Genotypes            |                           |                           |       |             |
| GG                    | 49 (44.14)                | 58 (58)                   | 0.008 | 1.31 (0.82–2.1) |
| GC                    | 44 (39.63)                | 38 (38)                   |       | 0.95 (0.57–1.60) |
| CC                    | 18 (16.21)                | 4 (4)                     |       | 0.24 (0.05–0.78) |
| HWE                   | 0.139                     | 0.466                     |       |             |
| GG:GC + CC            | 49 (44.14):62 (55.85)     | 58 (58):42 (42)           | >0.05 | 0.57 (0.31–1.02) |
| GG + GC:CC            | 93 (83.78):18 (16.21)     | 96 (96):4 (4)             | 0.003 | 0.21 (0.06–0.63) |
| Alleles               |                           |                           |       |             |
| G                     | 142 (69.98)               | 154 (77)                  | >0.05 | 1.10 (0.74–1.63) |
| C                     | 80 (36.03)                | 46 (23)                   |       |             |

Data were analyzed by χ² test. If p < 0.05 – not consistent with Hardy-Weinberg equilibrium (HWE). The results that are statistically significant are shown in italics.

Results

Baseline characteristics of the subjects according to the distributions of the MIF –173GC variant are shown in Table 1. The results of the genotype and allele frequencies of the MIF –173 variant in patient and control groups are presented in Table 2. Evaluation of variant within the –173GC region of MIF showed the presence of the GG genotype in 49 (44.14%) and 58 (58%), the GC genotype in 44 (39.63%) and 38 (38%), and the CC genotype in 18 (16.21%) and 4 (4%) patients and controls, respectively. The genotype dis-
tribution of the MIF –173GC variant was statistically different between the patients and controls (p = 0.008). The MIF –173GC variant CC genotype was more prevalent in the patient group (OR: 0.24, 95% CI: 0.05–0.078). A significant association was observed when the patients were compared with the controls according to GG + GC versus CC genotypes (p = 0.003; OR: 0.21, 95% CI: 0.06–0.063) (Table 2).

In this study, we detected the following: MIF –173GC alleles G (n = 142, 69.98%) and C (n = 80, 36.03%) in the BD patients, and G (n = 154, 77%) and C (n = 46, 23%) in the controls. Allele frequencies of the MIF –173GC variant did not show any statistically significant difference between patients and the controls (p > 0.05).

**Discussion**

In the present study, we investigated for the first time the association between the human MIF –173GC functional variant and BD in the Turkish population. The current study identified a significant association of the MIF –173GC with BD susceptibility. Our results show that in the Turkish population the MIF –173GC CC genotype was associated with an increased risk of BD (OR = 0.24) (Table 2). In addition, a significant association was observed when patients were compared with controls in terms of GG + GC versus CC genotypes (p = 0.003).

Overexpression of proinflammatory cytokines (mainly T helper 1 type) from various cellular sources appears to account for the increased inflammatory reaction in BD, and it may be related with a genetic tendency [11]. Besides cellular immune activation, the occurrence of autoantibodies against particular kinds of tissues (e.g., oral mucosa), endothelial antigens, and retinal proteins all suggest an abnormal humoral immune response. The activation of the inflammatory mechanism in BD is thought to be driven by proinflammatory cytokines including interleukin (IL)-1, IL-6, TNF-α, IL-8, and IL-10 which are increased in the sera of BD patients [11–14].

MIF, a crucial proinflammatory cytokine released by innate immune cells including macrophages and monocytes, could maintain proinflammatory function of macrophages by hindering p53-dependent apoptosis [15]. MIF is a largely expressed component of the immune system that is produced in response to various stimuli such as lipopolysaccharide (via toll-like receptor-4), proinflammatory cytokines including TNF-α and IFN-γ, and hypoxia [16]. MIF then upregulates the expression of toll-like receptor-4 and proinflammatory cytokines, and plays a role as a cofactor for the activation of T cells.

Research has shown that MIF levels are increased in patients with rheumatoid arthritis [17], systemic lupus erythematosus [18], insulin resistance [19], and type 2 diabetes mellitus [20]. As all these disorders are associated with persistent inflammation, it is important to elucidate the role of MIF in the pathogenesis of the disease. Furthermore, elevated MIF levels were found in the serum and cerebrospinal fluid of patients with multiple sclerosis and neuro-Behçet [21]. Also, the mean MIF levels in the sera of patients with Behçet’s uveitis and iridocyclitis were found to be higher than those of healthy control subjects [22, 23]. Also, it was reported that the mean serum level of MIF in patients with BD was higher in patients with BD than in healthy controls [24, 25].

The –173GC variant was the first MIF gene variant described in 2001 by Donn et al. [26]. Polymorphisms in promoters have an impact on the basal and/or induced transcription activity of MIF.

Coban et al. [27] reported that MIF –173GC variant C allele carriage tends to predict new-onset diabetes. Also, Ozsoy et al. [28] found that subjects carrying the variant C allele in the MIF –173 position were at a significantly higher risk of osteoporosis than subjects carrying the wild-type G allele in a Turkish population. In a previous study, it was found that the MIF –173GC variant was not associated with susceptibility to BD in Korean patients [29]. Also, Bahgat et al. [30] found that MIF gene –173GC and +254TC single-nucleotide polymorphisms were not implicated in the genetic susceptibility to BD among Egyptian patients. On the contrary, Zheng et al. [31] reported that frequencies of the MIF –173GC variant genotype GG and G allele were significantly decreased in BD patients compared to controls in the Han Chinese population. In addition, they showed that the expression of MIF mRNA in individuals carrying the CC genotype of the –173GC variant was 1.78- to 1.92-fold higher than in those carrying the GC or GG genotype.

**Conclusion**

We have demonstrated an association between the functional MIF –173GC variant and BD in a Turkish cohort. Our results reflect the small sample size of patients but we think it will help to enrich the data on the relation between the MIF –173GC variant and BD.

**Disclosure Statement**

There are no conflicts of interest.
References

1. Pekiner FN, Aytugar E, Demirel GY, et al: HLA-A, B (class I) and HLA-DR, DQ (class II) antigens in Turkish patients with recurrent aphthous ulceration and Behçet’s disease. Med Princ Pract 2013;22:464–468.

2. Scherrer MAR, Rocha VB, Garcia LC: Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol 2017;92:452–464.

3. Dilek K, Oçşimena AA, Sarıcaoglu H, et al: Cytokine gene polymorphisms in Behçet’s disease and their association with clinical and laboratory findings. Clin Exp Rheumatol 2009;27(suppl 53):573–578.

4. Kasama T, Ohtsuka K, Sato M, et al: Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases. Arthritis 2010;2010:106202.

5. Li Y, Yuan T, Lu W, et al: Association of tuberculosis and polymorphisms in the promoter region of macrophage migration inhibitory factor (MIF) in a Southwestern China Han population. Cytokine 2012;60:64–67.

6. Baugh JA, Chitnis S, Donnelly SC, et al: A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 2002;3:170–176.

7. De Benedetti F, Meazza C, Vivarelli M, et al: Functional and prognostic relevance of the −173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2003;48:1398–1407.

8. Wu J, Chen F, Zhang X, et al: Association of MIF promoter polymorphisms with psoriasis in a Han population in northeastern China. J Dermatol Sci 2009;53:212–215.

9. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990;335:1078–1080.

10. Wang FF, Huang XF, Shen N, et al: A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. Arthritis Res Ther 2013;15:R65.

11. Hamzaoui K, Hamzaoui A, Guemira F, et al: Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 2002;31:205–210.

12. Yosipovitch G, Shohat B, Bshara J, et al: Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet’s disease: correlations with disease activity and severity. Isr J Med Sci 1995;31:345–348.

13. Adam B, Calikoglu E: Serum interleukin-6, prococollagen and C-reactive protein levels in subjects with active Behçet’s disease. J Eur Acad Dermatol Venereol 2004;18:318–320.

14. Akdeniz N, Erezoglu M, Keley MS, et al: Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behçet’s disease. Ann Acad Med Singapore 2004;33:596–569.

15. Zhang K, Pan X, Shu X, et al: Relationship between MIF –173 G/C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver cirrhosis. Cell Immunol 2013;282:113–116.

16. Simons D, Grieb G, Hristov M, et al: Hypoxia-induced endothelial secretion of macrophage migration inhibitory factor and role in endothelial progenitor cell recruitment. J Cell Mol Med 2011;15:668–678.

17. Llanas-Covarrubias MA, Valles Y, Navarro-Hernández RE, et al: Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course. Rheumatol Int 2012;32:2307–2311.

18. De la Cruz-Mosso U, Bucala R, Palafoux-Sánchez CA, et al: Macrophage migration inhibitory factor: association of −794 CATT5–8 and –173 G/C polymorphisms with TNF-a in systemic lupus erythematosus. Hum Immunol 2014;75:433–439.

19. Vozarova B, Stefan N, Hanson R, et al: Plasma concentrations of macrophage migration inhibitory factor are elevated in Pima Indians compared to Caucasians and are associated with insulin resistance. Diabetologia 2002;45:1739–1741.

20. Yabunaka N, Nishihira J, Mizue Y, et al: Elevated serum content of macrophage migration inhibitory factor in patients with type 2 diabetes. Diabetes Care 2000;23:256–258.

21. Niino M, Ogata A, Kikuchi S, et al: Increased macrophage migration inhibitory factor in patients with Behcet’s disease. J Eur Acad Dermatol Venereol 2000;211.

22. Kim JS, Choi J, Hahn HJ, et al: Association of macrophage migration inhibitory factor polymorphisms with total plasma IgE levels in patients with atopic dermatitis in Korea. PLoS One 2016;11:e0162477.

23. Kitachi N, Kotake S, Mizue Y, et al: Increase of macrophage migration inhibitory factor in sera of patients with iridocyclitis. Br J Ophthalmol 2000;84:1423–1425.

24. Kim SD, Kim SH, Kim HR, et al: Elevated serum levels of macrophage migration inhibitory factor (MIF) in patients with Behcet’s disease. J Korean Rheum Assoc 2004;11:205–211.

25. Seraslan G, Soğut S, Yonden Z, et al: Increased macrophage migration inhibitory factor in Behçet’s disease and relation with the disease activity. J Eur Acad Dermatol Venereol 2009;23:1344–1346.

26. Dong BP, Shelley E, Ollier WE, et al: A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2001;44:1782–1785.

27. Coban N, Onat A, Yıldırım O, et al: Oxidative stress-mediated (sex-specific) loss of protection against type-2 diabetes by macrophage migration inhibitory factor (MIF) –173G/C polymorphism. Clin Chim Acta 2015;438:1–6.

28. Ozsoy AZ, Karakus N, Tural S, et al: Influence of the MIF polymorphism –173G > C on Turkish postmenopausal women with osteoporosis. Z Rheumatol 2017, Epub ahead of print.–

29. In SI, Baek JA, Park KS, et al: Expression of macrophage migration inhibitory factor in Behçet’s disease. J Korean Dermatol 2008;46:611–618.

30. Bahgat DMR, Said S, Gheithe R: Non-significant influence of macrophage migration inhibitory factor (MIF) promoter gene polymorphisms on the risk or activity of Egyptian Behçet’s disease patients: potential role of MIF+254T/C in posterior uveitis. Egyptian Rheumatologist 2017;39:115–120.

31. Zheng X, Wang D, Hou S, et al: Association of macrophage migration inhibitory factor gene polymorphisms with Behçet’s disease in a Han Chinese population. Ophthalmology 2012;119:2514–2518.